Patents by Inventor Stephen Edmund GOTTSCHLING

Stephen Edmund GOTTSCHLING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORM OF SELINEXOR
    Publication number: 20230391754
    Abstract: The invention relates to a crystalline form of the compound represented by Structural Formula 1, and pharmaceutical compositions comprising the crystalline form of the compound represented by Structural Formula 1 described herein. The crystalline form of the compound of Structural Formula 1 and compositions comprising the crystalline form of the compound represented by Structural Formula 1 provided herein, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline form of the compound represented by Structural Formula 1.
    Type: Application
    Filed: October 21, 2021
    Publication date: December 7, 2023
    Inventors: Sean Howard Wiedemann, Bojan Dragisic, Stephen Edmund Gottschling
  • CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF
    Publication number: 20230382942
    Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 30, 2023
    Inventors: Andrew M. K. Pennell, Eric F. Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
  • Crystalline forms of a CD73 inhibitor and uses thereof
    Patent number: 11649261
    Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: May 16, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Andrew M. K. Pennell, Eric F. Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
  • CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF
    Publication number: 20210395291
    Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 23, 2021
    Inventors: Andrew M. K. PENNELL, Eric F. CONNOR, Stephen Edmund GOTTSCHLING, Jim Dimetrios COLOMVAKOS, Mohammed Asadullah KHAN